Last $173.27 USD
Change Today -1.20 / -0.69%
Volume 1.4M
As of 8:10 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

alexion pharmaceuticals inc (ALXN) Snapshot

Open
$175.00
Previous Close
$174.48
Day High
$175.09
Day Low
$170.22
52 Week High
02/25/14 - $185.43
52 Week Low
10/23/13 - $106.83
Market Cap
34.3B
Average Volume 10 Days
1.5M
EPS TTM
$2.15
Shares Outstanding
197.8M
EX-Date
--
P/E TM
80.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for ALEXION PHARMACEUTICALS INC (ALXN)

alexion pharmaceuticals inc (ALXN) Related Businessweek News

View More BusinessWeek News

alexion pharmaceuticals inc (ALXN) Details

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.

1,774 Employees
Last Reported Date: 02/10/14
Founded in 1992

alexion pharmaceuticals inc (ALXN) Top Compensated Officers

Co-Founder, Chairman of the Board and Chief E...
Total Annual Compensation: $1.2M
Co-Founder, Chief Global Operations Officer a...
Total Annual Compensation: $607.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $615.0K
Global Head of Research & Development and Exe...
Total Annual Compensation: $547.0K
Chief Strategy & Portfolio Officer and Senior...
Total Annual Compensation: $325.0K
Compensation as of Fiscal Year 2013.

alexion pharmaceuticals inc (ALXN) Key Developments

Alexion Pharmaceuticals, Inc. Announces Executive Appointments

The Board of Directors of Alexion Pharmaceuticals, Inc. announced that Leonard Bell, M.D. has been appointed Chairman of the Board of Directors. Dr. Bell, principal founder of Alexion, continues to serve as Chief Executive Officer of the Company. Additionally, R. Douglas Norby has been appointed to the newly created Board position of Lead Independent Director. Mr. Norby, who was voted Lead Independent Director by the other independent members of the Board, has been a Director of Alexion since September 1999. Mr. Norby currently serves as Chair of the Audit Committee, a member of the Nominating and Corporate Governance Committee, and a member of the risk and strategy committee.

Alexion Pharmaceuticals, Inc. Announces Passing of Max Link, Chairman of Board of Directors

Alexion Pharmaceuticals, Inc. announced that Max Link, Ph.D., Chairman of the Board of Directors of Alexion, passed away unexpectedly on October 5 while traveling on business.

Alexion Pharmaceuticals, Inc. Announces Executive Appointments

Alexion Pharmaceuticals, Inc. announced key measures to strengthen and broaden its executive leadership team in line with the company's expanding global mission to develop and commercialize life-transforming therapies for patients with severe and rare disorders. David Hallal is being promoted to the newly created position of Chief Operating Officer and has been appointed to Alexion's Board of Directors. Mr. Hallal had previously served as Executive Vice President and Chief Commercial Officer, and will continue to lead all commercial operations globally with responsibility for country operations in each of Alexion's affiliates in EMEA, Japan, Australasia, and Latin America. As Chief Operating Officer, Mr. Hallal will additionally now lead key enterprise-wide initiatives and he will expand his role with external stakeholders. Clare Carmichael is being promoted to Executive Vice President and Chief Human Resources Officer (CHRO) from her previous position of Senior Vice President and CHRO. Ms. Carmichael will continue to lead and significantly expand the Company's global talent initiatives including talent management, talent acquisition, training and development, and compensation and benefits. John Moriarty, J.D. is being promoted to Executive Vice President and General Counsel from his previous position of Senior Vice President and General Counsel. Mr. Moriarty will continue to lead all of the Company's legal, government affairs and corporate communications activities, further expanding each of these functions to support the Company's ongoing global growth. Additionally, the company is also announced that Edward Miller, J.D. has joined Alexion in the newly created position of Senior Vice President and Chief Compliance Officer. Mr. Miller will lead all corporate compliance functions globally for Alexion. Mr. Miller will lead all compliance functions globally for Alexion. From 2000 to 2013, Mr. Miller held numerous compliance and legal leadership positions at Boehringer Ingelheim Pharmaceuticals/Boehringer Ingelheim GmbH, including Vice President, Associate General Counsel, Global Litigation & Government Investigations, Vice President/Acting Global Compliance Officer, Vice President, Chief Compliance Officer and Head of Litigation, and Chief Compliance Officer, Head of Litigation. All four executives will report directly to Dr. Bell. The promotions of Mr. Hallal, Ms. Carmichael, and Mr. Moriarty, and the addition of Mr. Miller, are designed to facilitate the further growth of Alexion to serve more patients with severe and devastating disorders around the world.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALXN:US $173.27 USD -1.20

ALXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Croda International PLC 2,215 GBp +122.00
Dr Reddy's Laboratories Ltd 3,038 INR 0.00
Regeneron Pharmaceuticals Inc $384.46 USD +3.45
Sigma-Aldrich Corp $135.85 USD +0.25
Symrise AG €42.04 EUR +0.133
View Industry Companies
 

Industry Analysis

ALXN

Industry Average

Valuation ALXN Industry Range
Price/Earnings 84.6x
Price/Sales 17.3x
Price/Book 11.6x
Price/Cash Flow 83.0x
TEV/Sales 16.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEXION PHARMACEUTICALS INC, please visit www.alexionpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.